Disclosed is the use of an alpha2delta calcium channel subunit (A2d) ligand, where said A2d ligand is one or more species independently selected from the list consisting of gabapentin, pregabalin, (1R,5R,6S)-6-aminomethyl-6-carboxymethyl-bicyclo[3.2.0]heptane, 3-(1-aminomethylcyclohexylmethyl)-4H-1,2,4-oxadiazol-5-one, 5-(1-aminomethyl-cyclohexylmethyl)-1Htetrazole, (3S,4S)-(1-aminomethyl-1-carboxymethyl-3,4-dimethyl-cyclopentane, (1á,3á,5á)-(3-aminomethyl-3-carboxymethyl-bicyclo[3.2.0]heptane, (3S,5R)-3-aminomethyl-5-methyloctanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (2S,4S)-4-(3-chlorophenoxy)-proline and (2S,4S)-4-(3-fluorobenzyl)-proline, for the preparation of a medicament which is formulated for prior, concurrent or post-administration with a non-steroidal anti-inflammatory drug (NSAID) for the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder, where the prior or post administration of the NSAID is within such a period as to act synergistically with the A2d ligand. Also disclosed is the use of a non-steroidal anti-inflammatory drug (NSAID) for the preparation of a medicament for the treatment of urinary incontinence in a subject suffering from a lower urinary tract disorder in combination with the prior, concurrent or post-administration of an alpha2delta calcium channel subunit (A2d) ligand as listed above. Particular NSAIDs are COX-inhibitors celecoxib, diclofenac, diflunisal, flurbiprofen, naproxen, nimesulide and sulindac.
